Literature DB >> 29491748

Use of Electronic Health Record Tools to Facilitate and Audit Infliximab Prescribing.

Bethany R Sharpless, Fernando Del Rosario, Zarela Molle-Rios, Elora Hilmas.   

Abstract

OBJECTIVES: The objective of this project was to assess a pediatric institution's use of infliximab and develop and evaluate electronic health record tools to improve safety and efficiency of infliximab ordering through auditing and improved communication.
METHODS: Best use of infliximab was defined through a literature review, analysis of baseline use of infliximab at our institution, and distribution and analysis of a national survey. Auditing and order communication were optimized through implementation of mandatory indications in the infliximab orderable and creation of an interactive flowsheet that collects discrete and free-text data. The value of the implemented electronic health record tools was assessed at the conclusion of the project.
RESULTS: Baseline analysis determined that 93.8% of orders were dosed appropriately according to the findings of a literature review. After implementation of the flowsheet and indications, the time to perform an audit of use was reduced from 60 minutes to 5 minutes per month. Four months post implementation, data were entered by 60% of the pediatric gastroenterologists at our institution on 15.3% of all encounters for infliximab. Users were surveyed on the value of the tools, with 100% planning to continue using the workflow, and 82% stating the tools frequently improve the efficiency and safety of infliximab prescribing.
CONCLUSIONS: Creation of a standard workflow by using an interactive flowsheet has improved auditing ability and facilitated the communication of important order information surrounding infliximab. Providers and pharmacists feel these tools improve the safety and efficiency of infliximab ordering, and auditing data reveal that the tools are being used.

Keywords:  EHR tool; EMR tool; Epic; drug audit; infliximab

Year:  2018        PMID: 29491748      PMCID: PMC5823488          DOI: 10.5863/1551-6776-23.1.18

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  11 in total

1.  American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.

Authors:  Michael Clark; Jean-Frederic Colombel; Brian C Feagan; Richard N Fedorak; Stephen B Hanauer; Michael A Kamm; Lloyd Mayer; Carol Regueiro; Paul Rutgeerts; William J Sandborn; Bruce E Sands; Stefan Schreiber; Stephan Targan; Simon Travis; Severine Vermeire
Journal:  Gastroenterology       Date:  2007-07       Impact factor: 22.682

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.

Authors:  Bhupinder K Sandhu; John M E Fell; R Mark Beattie; Sally G Mitton; David C Wilson; Huw Jenkins
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-02       Impact factor: 2.839

4.  Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.

Authors:  K T Park; Aaron Sin; May Wu; Dorsey Bass; Jay Bhattacharya
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 5.  Pediatric ulcerative colitis: a practical guide to management.

Authors:  Brian P Regan; Athos Bousvaros
Journal:  Paediatr Drugs       Date:  2014-06       Impact factor: 3.022

6.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

7.  High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice.

Authors:  Roy Nattiv; Janet M Wojcicki; Elizabeth A Garnett; Neera Gupta; Melvin B Heyman
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

8.  A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.

Authors:  Nicolino Ruperto; Daniel J Lovell; Ruben Cuttica; Nick Wilkinson; Patricia Woo; Graciela Espada; Carine Wouters; Earl D Silverman; Zsolt Balogh; Michael Henrickson; Maria-Teresa Apaz; Eileen Baildam; Anders Fasth; Valeria Gerloni; Pekka Lahdenne; Anne-Marie Prieur; Angelo Ravelli; Rotraud K Saurenmann; Maria Luz Gamir; Nico Wulffraat; Laszlo Marodi; Ross E Petty; Rik Joos; Francesco Zulian; Deborah McCurdy; Barry L Myones; Kalman Nagy; Peter Reuman; Ilona Szer; Suzanne Travers; Anna Beutler; Greg Keenan; Jason Clark; Sudha Visvanathan; Adedigbo Fasanmade; Aparna Raychaudhuri; Alan Mendelsohn; Alberto Martini; Edward H Giannini
Journal:  Arthritis Rheum       Date:  2007-09

9.  Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Authors:  Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864

10.  Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines.

Authors:  Dan Turner; Arie Levine; Johanna C Escher; Anne M Griffiths; Richard K Russell; Axel Dignass; Jorge Amil Dias; Jiri Bronsky; Christian P Braegger; Salvatore Cucchiara; Lissy de Ridder; Ulrika L Fagerberg; Séamus Hussey; Jean-Pierre Hugot; Sanja Kolacek; Kaija Leena Kolho; Paolo Lionetti; Anders Paerregaard; Alexander Potapov; Risto Rintala; Daniela E Serban; Annamaria Staiano; Brian Sweeny; Gigi Veerman; Gabor Veres; David C Wilson; Frank M Ruemmele
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-09       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.